Nav1.7 withholds its pain potential

Despite compelling genetic validation, drug developers are struggling to unlock the therapeutic promise of the Nav1.7 sodium channel as a pain target.

Search for this author in:

Credit: Stocktrek Images, Inc./Alamy Stock Photo

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 18, 321-323 (2019)

doi: 10.1038/d41573-019-00065-0

Updates & Corrections

  • Clarification 10 April 2019: Clarification has been made regarding the researchers responsible for using induced pluripotent stem cell technology to create Nav1.7-knockout nociceptors, and the researchers developing functional brain imaging markers of pain.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.